Radiotherapy and Oncology - McMaster Experts

publication venue for

CANADIAN KIDNEY CANCER PATIENTS' TREATMENT PREFERENCES FOR EARLY-STAGE DISEASE 2024
PHASE II RANDOMIZED TRIAL OF OPTIMAL RECURRENCE-DIRECTED THERAPY (RDT) WITHOUT OR WITH ANDROGEN-DEPRIVATION THERAPY (ADT) IN RADIO-RECURRENT OLIGO-METASTATIC HORMONE/CASTRATE SENSITIVE PROSTATE CANCER (ROMCSPC): THE OCOG-RATIONAL-PCS TRIAL 2024
PROGRAM DIRECTOR PERSPECTIVES ON THE IMPLEMENTATION AND EXPERIENCES OF THE COMPETENCE BY DESIGN CURRICULUM IN CANADIAN RADIATION ONCOLOGY TRAINING PROGRAMS 2024
STEREOTACTIC BODY RADIOTHERAPY FOR PARA-AORTIC LYMPH NODES FOR GYNAECOLOGICAL CANCERS 2024
STEREOTACTIC BODY VERSUS CONVENTIONAL FRACTIONATION EXTERNAL BEAM RADIOTHERAPY (EBRT) BOOST FOR HIGH-RISK PROSTATE CANCER (HR-PC); EARLY RESULTS OF PBS: A PHASE II RANDOMIZED TRIAL (NCT03380806) 2024
Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16 2024
Proton arc therapy: advantages over conventional proton therapy and impact on range uncertainties 2024
COMPARISON OF PATIENT-SPECIFIC QUALITY ASSURANCE RESULTS FROM A DELIVER-LOG BASED CALCULATION SYSTEM AND DOSE RECONSTRUCTION IN PATIENT ANATOMY BASED ON PHANTOM MEASUREMENTS 2023
EVALUATION OF VOLUMETRIC RESPONSE ASSESSMENT FROM STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR RENAL CELL CARCINOMA (RCC) 2023
FINAL RESULTS FROM A PROSPECTIVE RANDOMIZED PILOT TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VERSUS RADIOFREQUENCY ABLATION FOR THE MANAGEMENT OF SMALL RENAL MASSES (RADSTER) 2023
FIVE-YEAR RENAL FUNCTION OUTCOMES AFTER SABR FOR PRIMARY RENAL CELL CARCINOMA: A REPORT FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM OF THE KIDNEY (IROCK) 2023
LONG-TERM TOXICITY IN PATIENTS RECEIVING RADIOTHERAPY FOR ULTRACENTRAL STAGE I NON-SMALL CELL LUNG CANCER - A SECONDARY ANALYSIS OF THE LUSTRE RANDOMIZED TRIAL 2023
PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY FOR PATIENTS WITH RECURRENT PROSTATE CANCER (PREP) - A PROSPECTIVE, MULTICENTRE REGISTRY 2023
PROTON THERAPY MEDIATES DOSE REDUCTIONS TO CRITICAL BRAIN ORGANS AT RISK WHICH ARE ASSOCIATED WITH BETTER COGNITION IN CHILDREN WITH MEDULLOBLASTOMA 2023
STEREOTACTIC BODY RADIATION THERAPY (SBRT) AND HYPO-FRACTIONATED RADIATION THERAPY (HFRT) OUTCOMES FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER (PRCA): EXPERIENCE AT TWO ONTARIO CENTRES 2023
STEREOTACTIC RADIOTHERAPY FOR THE RE-TREATMENT OF PELVIC AND PARA-AORTIC DISEASE IN GYNECOLOGIC CANCERS 2023
THE EFFECTIVENESS AND SAFETY OF STEREOTACTIC BODY RADIATION THERAPY IN THE TREATMENT OF OLIGOPROGRESSIVE BREAST CANCER: A SYSTEMATIC REVIEW 2023
TOWARDS AI-BASED DOSE PREDICTION OF DAILY DELIVERED DOSE DURING LUNG CANCER RADIOTHERAPY 2023
Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation 2023
A PROSPECTIVE RANDOMIZED PARALLEL-CONTROLLED PILOT TRIAL OF STEREOTACTIC BODY RADIATION THERAPY VERSUS RADIOFREQUENCY ABLATION FOR THE MANAGEMENT OF SMALL RENAL MASSES - INITIAL RESULTS 2022
FIRST PAN-CANADIAN CONSENSUS RECOMMENDATIONS FOR PROTON BEAM THERAPY ACCESS IN CANADA 2022
INCIDENCE AND MANAGEMENT TRENDS IN LOCALLY ADVANCED HEAD AND NECK NON-MELANOMA SKIN CANCER 2022
LONG-TERM OUTCOMES OF SABR TO PRIMARY RENAL CELL CARCINOMA: A MULTI- CENTRE ANALYSIS FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM FOR KIDNEY (IROCK) 2022
OUTCOMES OF RADIOTHERAPY ALONE FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) IN PATIENTS UNFIT FOR CHEMO-RADIOTHERAPY 2022
RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER 2022
RADIOTHERAPY DOSE, FDG-PET UTILIZATION AND SURVIVAL OUTCOMES OF UNRESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC). ONTARIO POPULATION OUTCOMES OF CONTEMPORARY RADIOTHERAPY ALONE AND STANDARD OF CARE CHEMO-RADIOTHERAPY 2022
STATIN THERAPY IN PATIENTS UNDERGOING SHORT-COURSE NEOADJUVANT RADIOTHERAPY FOR RECTAL CANCER 2022
STEREOTACTIC BODY RADIOTHERAPY FOR RENAL CELL CARCINOMA: ONCOLOGIC AND RENAL FUNCTION OUTCOMES 2022
THE EVOLUTION OF TECHNOLOGY IN THE MANAGEMENT OF EARLY-STAGE (T1) CANCER OF THE LARYNX, AN INSTITUTIONAL REVIEW OF RADIATION THERAPY OUTCOMES 2022
First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects 2022
52: Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease 2021
CHANGES IN THE INCIDENCE OF CERVICAL SQUAMOUS CARCINOMA/CARCINOMA IN SITU IN ONTARIO FOLLOWING THE APPROVAL OF A HUMAN PAPILLOMAVIRUS VACCINE 2021
COMPARISON OF RECURRENCE WITH HIGH RETROPHARYNGEAL NODAL-SPARING RADIATION TECHNIQUE IN HPV-RELATED AND HPV-UNRELATED OROPHARYNGEAL CANCER IN THE IMRT ERA 2021
COST-EFFECTIVENESS OF SABR IN OLIGOMETASTATIC CANCER: AN ECONOMIC ANALYSIS BASED ON LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL 2021
PROSTATE SBRT BOOST RADIOTHERAPY (PBS TRIAL): A RANDOMIZED PHASE II TRIAL OF SBRT VERSUS CONVENTIONALLY-FRACTIONATED RADIOTHERAPY BOOST FOLLOWING PELVIC RADIOTHERAPY IN HIGH-RISK PROSTATE CANCER 2021
PSMA-PET-BASED RESPONSE ASSESSMENT OF METASTATIC PROSTATE CANCER RESPONSE TO RADIOTHERAPY: A CASE SERIES 2021
REAL-WORLD OUTCOMES OF CHEMORADIATION AND CONSOLIDATIVE DURVALUMAB IN UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER - A SYSTEMATIC REVIEW 2021
STEREOTACTIC PELVIC ADJUVANT RADIATION THERAPY IN CANCERS OF THE UTERUS (SPARTACUS): A MULTI-CENTRE PROSPECTIVE TRIAL EVALUATING ACUTE TOXICITIES AND PATIENT REPORTED OUTCOMES 2021
THE ROLE OF FDG-PET IN STAGING AND TREATMENT FOR STAGE III NSCLC IN ONTARIO BETWEEN 2009-2017 2021
UNDERSTANDING END-OF-LIFE CANCER CARE IN CANADA: AN UPDATED 12-YEAR RETROSPECTIVE ANALYSIS OF THREE PROVINCES' ADMINISTRATIVE HEALTH CARE DATA 2021
Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy) 2021
PD-0911 Real world utilization of radical local therapy in metastatic castrate sensitive prostate cancer 2021
Real world utilization of radical local therapy in metastatic castrate sensitive prostate cancer 2021
152: Toxicity Assessment of Individualized Dosimetry Adjusted PRRT - Interim Report of the Ontario Consortium Trial OZM 067 2020
A PHASE II MULTICENTRE TRIAL OF STEREOTACTIC RADIOTHERAPY FOR OLIGOPROGRESSION IN METASTATIC KIDNEY CANCER PATIENTS RECEIVING TYROSINE KINASE INHIBITOR THERAPY 2020
A PROSPECTIVE PROVINCIAL PSMA-PET REGISTRY FOR RECURRENT PROSTATE CANCER: PRELIMINARY RESULTS 2020
A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL 2020
CARDIAC MORBIDITY FOLLOWING RADICAL THORACIC CHEMORADIOTHERAPY FOR LOCALLY ADVANCED LUNG CANCER: A POPULATION-BASED COHORT STUDY 2020
CARDIAC TOXICITY IN CENTRAL NON-SMALL CELL LUNG TUMOURS TREATED WITH STEREOTACTIC BODY RADATION THERAPY (SBRT) - IS THERE A "NO-FLUTTER ZONE"? 2020
COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION (RFA) VERSUS STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN THE TREATMENT OF LOCALIZED RENAL CELL CARCINOMA 2020
DOSIMETRIC COMPARISON OF CONFORMAL RADIATION THERAPY (CRT), IMRT AND VMAT FOR ESOPHAGEAL CANCER TREATED WITH EXTERNAL RADIATION 2020
ENABLING ACCESS TO CERVCIAL CANCER RADIOTHERAPY IN UGANDA: 10 YEAR UPDATE ON ROAD TO CARE 2020
INTRAOPERATIVE MRI-GUIDED BRACHYTHERAPY FOR CERVICAL CANCER: AN INSTITUTIONAL EXPERIENCE OF TREATMENT WORKFLOW, PLANNING AND PATIENT TOXICITY 2020
RADIATION DOSE TO ORGANS AT RISK AFTER HIGH DOSE RATE BRACHYTHERAPY FOR ESOPHAGEAL CANCER PATIENTS 2020
RADIOTHERAPY IN PATIENTS WITH CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES: A SURVEY OF MULTI-DISCIPLINARY RADIATION ONCOLOGY PROFESSIONALS 2020
STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) IN OLIGOMETASTATIC AND OLIGOPROGRESSIVE GYNECOLOGIC CANCERS: CLINICAL OUTCOMES OF A SINGLE INSTITUTION ANALYSIS 2020
STEREOTACTIC ABLATIVE RADIOTHERAPY FOR THE COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC CANCERS: LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL 2020
SURGERY VERSUS SBRT FOR EARLY-STAGE NSCLC IN OCTOGENARIANS AND NONAGENARIANS: AN OVERALL SURVIVAL DIFFERENCE? 2020
TOXICITY ASSESSMENT OF INDIVIDUALIZED DOSIMETRY ADJUSTED PRRT - INTERIM REPORT OF THE ONTARIO CONSORTIUM TRIAL OZM 067 2020
70 Quantifying Tumour Dose Using Individualized Dosimetry Methodology in 177LU Dotatate Therapy 2019
A COMPARISON OF STEREOTACTIC BODY RADIOTHERAPY MODALITIES: VOLUMETRIC MODULATED ARC THERAPY VERSUS INTENSITY MODULATED RADIATION THERAPY IN TREATMENT OF KIDNEY CANCER 2019
CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING CELLULAR METABOLISM, SUPPRESSES SURVIVAL AND ENHANCES THE RESPONSE OF NON-SMALL CELL LUNG CANCER (NSCLC) TO RADIOTHERAPY 2019
CHARACTERIZING THE INITIATION, COMPLETION, AND INTEGRATION OF ENTRUSTABLE PROFESSIONAL ACTIVITY ASSESSMENTS IN RADIATION ONCOLOGY RESIDENCY TRAINING AND CLINICAL WORKFLOW: AN INSTITUTIONAL PILOT OF COMPETENCE BY DESIGN 2019
CYBERKNIFE STEREOTACTIC RADIOSURGERY FOR TREATMENT OF BENIGN INTRACRANIAL MENINGIOMA: LONG-TERM SAFETY AND EFFICACY 2019
DRIVE: DEFINING RADIORECURRENT INTRAPROSTATIC TARGET VOLUMES 2019
ENGAGING INTER-PROFESSIONAL COLLABORATION TO IMPROVE RESIDENT TREATMENT PLANNING KNOWLEDGE AND SKILLS 2019
IMPACT OF PELVIC INTENSITY-MODULATED RADIOTHERAPY (IMRT) ON LYMPH NODE COVERAGE AND DOSE TO CRITICAL ORGANS, COMPARE TO THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT), IN LOCALIZED HIGH-RISK PROSTATE CANCER 2019
QUALITY OF LIFE OUTCOMES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) VERSUS STANDARD OF CARE PALLIATIVE TREATMENTS: A SECONDARY ANALYSIS OF THE SABR-COMET RANDOMIZED TRIAL 2019
QUANTIFYING TUMOUR DOSE USING INDIVIDUALIZED DOSIMETRY METHODOLOGY IN 177LU DOTATATE THERAPY 2019
THE IMPACT OF ROUTINE ESAS USE ON EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS: A POPULATION-BASED RETROSPECTIVE MATCHED COHORT STUDY 2019
THE NEW DIABETES DRUG CANAGLIFLOZIN ENHANCES THE RESPONSE OF PROSTATE CANCER TO RADIOTHERAPY 2019
PO-0833: Dosimetric analysis of renal toxicity after stereotactic body radiotherapy for renal cell carcinoma 2018
EP-1387: Time Trends In Opioid Use In Cancer Patients with Pain: Observations from Administrative Data 2017
OC-0452: Evaluation of a novel field placement algorithm for tangential internal mammary chain radiotherapy 2017
PO-0842: Choosing the best heart sparing technique for breast and internal mammary chain radiotherapy 2017
PV-0548: The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: a pooled analysis 2017
A PROSPECTIVE STUDY VALIDATING THE EORTC QLQ-BM22 BONE METASTASES MODULE IN PATIENTS WITH PAINFUL BONE METASTASES 2016
BRACHYTHERAPY AS A SOLE TREATMENT MODALITY FOR EARLY ESOPHAGEAL CANCER (EEC) 2016
BRACHYTHERAPY FOR ENDOBRONCHIAL METASTASIS: AN EFFECTIVE METHOD OF ACHIEVING PALLIATIVE RELIEF OF COUGH, HEMOPTYSIS, CHEST PAIN AND DYSPNEA 2016
COMBINED SALICYLATE (SAL) - METFORMIN (MET) TREATMENT INDUCES INCREASED TUMOUR SUPPRESSION AND RADIOSENSITIZATION IN PRECLINICAL MODELS OF PROSTATE CANCER (PRCA) 2016
COMPARISON OF EXISTING RISK STRATIFICATION TOOLS FOR LOCALIZED PROSTATE CANCER 2016
CURRENT PRACTICE OF BRACHYTHERAPY AND EXTERNAL BEAM RADIOTHERAPY FOR CERVICAL CANCER IN ONTARIO, CANADA 2016
CURRENT PRACTICE OF EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY FOR MANAGEMENT OF ENDOMETRIAL CANCER IN ONTARIO, CANADA 2016
EXTERNAL VALIDATION OF THE PROCARS NOMOGRAMS FOR LOCALIZED PROSTATE CANCER 2016
INDENTIFICATION OF CURCULATING MIRNA ASSOCIATED WITH DEVELOPMENT OF CASTRATE RESISTANCE IN HIGH-RISK AND BIOCHEMICALLY RECURRENT PROSTATE CANCER PATIENTS 2016
MINIMAL CLINICALLY IMPORTANT DIFFERENCES IN THE EORTC QLQ-BM22 AND EORTC QLQ-C15-PAL MODULES IN PATIENTS WITH BONE METASTASES 2016
PATHOLOGIC AND TREATMENT FACTORS ASSOCIATED WITH RECURRENCE IN STAGE IA SEROUS ADENOCARCINOMA OF THE UTERUS 2016
PHASE I STUDY OF NEO-ADJUVANT STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OPERABLE PATIENTS WITH BORDERLINE RESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) (LINNEARRE I STUDY: NCT02433574) 2016
SINONASAL UNDIFFERENTIATED CARCINOMA WITH BRAIN METASTASIS: A CASE REPORT AND REVIEW OF LITERATURE 2016
SYSTEMATIC REVIEW OF PATIENT REPORTED QUALITY OF LIFE FOLLOWING STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PRIMARY AND METASTATIC LIVER CANCER 2016
THE MANAGEMENT OF SMALL CELL LUNG CANCER WITH RADIOTHERAPY - A PAN-CANADIAN SURVEY OF RADIATION ONCOLOGISTS 2016
PO-0971: Production of Gd-153 as a source isotope for use in rotating shield high dose rate brachytherapy 2016
CogState computerized memory tests in patients with br ain metastases: Secondary endpoint results of RTOG 0933 2014
1284 poster AUTOMATED 2D/3D REGISTRATION FOR LUNG BRACHYTHERAPY 2011
536 oral RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY 2011
A POPULATION-BASED OUTCOMES ANALYSIS OF YOUNG WOMEN TREATED WITH BREAST-CONSERVING SURGERY AND RADIATION FOR DCIS: IS THERE A DIFFERENCE IN OUTCOMES AMONG COMMONLY USED FRACTIONATION SCHEMES? 2010
A PROSPECTIVE STUDY OF FDG-PET IMAGING IN ASSESSMENT OF RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA UNDERGOING SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT 2010
AN EDUCATIONAL PROGRAM IN ONCOLOGY FOR FAMILY MEDICINE TRAINEES 2010
ASSESSING CONFORMITY BETWEEN THE CLINICAL SPECIALIST RADIATION THERAPIST (CSRT) AND RADIATION ONCOLOGISTS FOR TARGET VOLUME DELINEATION AND FIELD PLACEMENT IN PALLIATIVE PATIENTS 2010
COMPARISON OF PROPHYLACTIC AND URGENT PERCUTANEOUS GASTROSTOMY TUBE PLACEMENT IN PATIENTS TREATED WITH COMBINED RADIATION AND CHEMOTHERAPY FOR HEAD AND NECK CANCER 2010
DOES 3D VERSUS 2D PLANNING TECHNIQUES MAKE A DIFFERENCE IN PALLIATIVE RADIOTHERAPY? 2010
EVALUATING THE FEASIBILITY OF TELEMEDICINE FOR NEW PATIENT CONSULTATIONS IN PALLIATIVE RADIOTHERAPY 2010
FEASIBILITY OF BONE MARROW SPARING USING INTENSITY MODULATED RADIOTHERAPY IN A PATIENT WITH INTERMEDIATE RISK PROSTATE CANCER AND COMPROMISED PLATELET COUNT DUE TO CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA. 2010
INTENSITY-MODULATED RADIOTHERAPY (IMRT) AND CONCURRENT CHEMOTHERAPY FOR ANAL AND PERIANAL CANCER: THE PRINCESS MARGARET HOSPITAL EXPERIENCE 2010
ONLINE PLANNING AND DELIVERY TECHNIQUE FOR PALLIATIVE RADIOTHERAPY OF BONE METASTASES 2010
SYMPTOM BURDEN AND PERFORMANCE STATUS IN A POPULATION BASED COHORT OF CANCER PATIENTS 2010
THREE-YEAR OUTCOMES OF A CANADIAN MULTI-CENTRE STUDY OF ACCELERATED PARTIAL BREAST IRRADIATION (APBI) USING CONFORMAL RADIATION THERAP 2010
110 ACTIVATORS OF AMP-ACTIVATED PROTEIN KINASE (AMPK) ENHANCE RADIATION RESPONSES IN LUNG CANCER CELLS 2009
126 FACTORS INFLUENCING DOSE/FRACTIONATION CHOICES FOR PALLIATION OF BONE METASTASES 2009
136 DOSIMETRIC COMPARISON OF DIFFERENT DOSE PRESCRIPTIONS AND BEAM WEIGHTINGS FOR VOLUMETRIC TREATMENT PLANS FOR VERTEBRAL METASTASES 2009
154 HEALTH SYSTEM CHARACTERISTICS ASSOCIATED WITH PATTERNS OF PALLITIVE CARE USE IN ONTARIO 2009
163 OUTCOMES AND PREDICTORS OF SURVIVAL FOLLOWING CONCOMITANT AND ADJUVANT TEMOZOLOMIDE WITH RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME 2009
17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA 2009
182 INTENSITY MODULATED RADIOTHERAPY (IMRT) AND CONCURRENT CHEMOTHERAPY (CHT) FOR ANAL AND PERIANAL CANCER: PRELIMINARY REPORT OF ACUTE TOXICITY 2009
193 PHOTODYNAMIC THERAPY AS A TREATMENT OPTION FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LOWER EXTREMITY 2009
30 PET START: THE FIRST RANDOMIZED CLINICAL TRIAL EVALUATING THE IMPACT OF POSITRON EMISSION TOMOGRAPHY IN STAGE III NON-SMALL CELL LUNG CANCER 2009
44 COPY NUMBER ALTERATION PREDICTS FOR BIOCHEMICAL RECURRENCE IN LOCALIZED PROSTATE CANCER USING HIGHRESOLUTION ARRAY COMPARATIVE GENOMIC HYBRIDIZATION 2009
46 IONIZING RADIATION ACTIVATES AMP – ACTIVATED PROTEIN KINASE (AMPK) IN HUMAN EPITHELIAL TUMOUR CELLS THROUGH AN LKB1-INDEPENDENT AND ATM-DEPENDENT PATHWAY 2009
52 IMPLEMENTATION OF A SEMI-AUTOMATIC VERTEBRA DETECTION AND SEGMENTATION ALGORITHM FOR RADIOTHERAPY OF SPINOUS BONE METASTASES 2009
63 DYSPAREUNIA AFTER CHEMORADIATION (CHEMO-RT) FOR ANAL CARCINOMA -AN UNDER REPORTED COMPLICATION 2009
87 DEVELOPING CONSENSUS AMONG CLINICAL EXPERTS AND NONEXPERTS FOR THE ROLE OF POSITRON EMISSION TOMOGRAPHY IN SMALL CELL LUNG CANCER 2009
99 DEVELOPMENT OF A CANADIAN PALLIATIVE RADIATION ONCOLOGY CURRICULUM 2009
A CANADIAN MULTI-CENTRED ASSESSMENT OF CANCER PAIN MANAGEMENT USING THE PAIN MANAGEMENT INDEX 2009
FUNGAL INFECTION IS A SIGNIFICANT CAUSE OF ODYNOPHAGIA IN ESOPHAGEAL CANCER PATIENTS AFTER BRACHYTHERAPY 2009
A POPULATION - BASED STUDY OF THE FRACTIONATION OF POST - LUMPECTOMY BREAST RADIOTHERAPY IN ONTARIO 2008
A POPULATION-BASED STUDY OF THE FRACTIONATION OF POST-LUMPECTOMY BREAST RADIOTHERAPY IN ONTARIO 2008
A PROSPECTIVE EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH GASTRIC ADENOCARCINOMA IN A PHASE I STUDY OF ADJUVANT CHEMORADIATION 2008
A RETROSPECTIVE REVIEW OF THE INCIDENCE OF BRAIN METASTASES IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER 2008
ACUTE URINARY MORBIDITY OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: DO PATIENTS UNDERGOING CONFORMAL RADIATION THERAPY WITH IMPLANTED GOLD SEEDS HAVE MORE URINARY SYMPTOMS DURING RADIATION THERAPY? 2008
ADJUVANT EXTERNAL BEAM RADIOTHERAPY IN THE TREATMENT OF ENDOMETRIAL CANCER: RESULTS OF THE RANDOMIZED MRC ASTEC AND NCIC EN.5 TRIALS, A SYSTEMATIC REVIEW AND META-ANALYSIS 2008
AGE AND SEX-SPECIFIC ESTIMATES OF CARDIOVASCULAR MORBIDITY FOLLOWING MODERN TREATMENT FOR HODGKIN'S LYMPHOMA: INCREASED RISK IN THE DOXORUBICIN ERA 2008
CONSTRUCTION AND TESTING OF A SYMPTOM CHECK-LIST FOR PATIENTS WITH BRAIN METASTASES 2008
DELIVERY OF LESS THAN INTENDED CISPLATIN (COOP) DOSE INTENSITY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) RECEIVING CONCURRENT CHEMORADIATION (CRT) CORRELATES WITH POORER OUTCOME 2008
DOSIMETRIC EVALUATION OF STABILIZING NEEDLES AND SEMINAL VESICLE IMPLANTS FOR LDR PROSTATE BRACHYTHERAPY 2008
EVALUATION OF TUMOUR BED LOCALISATION AND IMAGE-GUIDED RADIOTHERAPY FOR BREAST CANCER: THE IMPORT GOLD SEED STUDY 2008
IMPACT OF BLADDER FILLING (FULL OR EMPTY) ON DOSE VOLUME HISTOGRAMS IN RADIATION PLANNING FOR POST-PROSTATECTOMY PATIENTS 2008
INFLUENCE OF GOLD SEED IMPLANTATION ON DEFINING TARGET VOLUMES FOR CONFORMAL RADIOTHERAPY OF PROSTATE CANCER 2008
INTEGRATING FAMILY PHYSICIANS INTO CANCER CARE 2008
INVESTIGATING RESVERATROL IN COMBINATION WITH RADIATION IN PROSTATE CANCER 2008
LONG-TERM RESULTS OF A RANDOMIZED TRIAL OF ACCELERATED HYPOFRACTIONATED WHOLE BREAST IRRADIATION FOLLOWING BREAST CONSERVING SURGERY IN WOMEN WITH NODE-NEGATIVE BREAST CANCER 2008
LOVASTATIN SENSITIZES NON-SMALL CELL LUNG CANCER (NSCLC) CELLS TO RADIATION; POSSIBLE INVOLVEMENT OF THE AKT SIGNALING PATHWAY 2008
MALIGNANT SPINAL CORD COMPRESSION: IDENTIFYING PATIENTS SUITABLE FOR SURGERY 2008
PALLIATIVE RADIOTHERAPY - HOW TO COPE WITH MULTIPLE PREVIOUS TREATMENT VOLUMES IN THE ELECTRONIC AGE 2008
PRELIMINARY RESULTS OF A PHASE II STUDY OF SINGLE FRACTION PALLIATIVE RADIOTHERAPY FOR SYMPTOMATIC HEPATOCELLULAR CARCINOMA AND LIVER METASTASES 2008
THE IMPORT HIGH PLANNING STUDY: DEFINING DOSE CONSTRAINTS AND TREATMENT PLANNING METHODS FOR COMPLEX BREAST RADIOTHERAPY 2008
THE USE OF RADIATION THERAPY IN THE RADICAL TREATMENT OF RECTAL CANCER: A POPULATION BASED STUDY 2008
TWO-YEAR RESULTS OF THE CANADIAN FEASIBILITY STUDY OF ACCELERATED PARTIAL BREAST IRRADIATION (APBI) USING 3D CONFORMAL RADIATION THERAPY (3D-CRT) 2008
A low-dose ipsilateral lung constraint improves planning for partial breast irradiation 2007
A phase I study of concurrent pemetrexed Cisplatin radiation for unresectable stage IIIA/B non-small cell lung cancer 2007
A simple approach for quantitative imaging of fluorescent point sources in small animals 2007
Apoptotic cell death detection by high-frequency ultrasound spectroscopy; Monitoring of photodynamic therapy in vivo 2007
CT imaging in cervical cancer: Determination of dose delivered to bladder and rectum during intracavitary brachytherapy 2007
Can we standardize steroid dose in patients with brain metastases? A prospective study 2007
Credentialing of radiation oncologists' seroma contouring for the randomized trial of accelerated partial breast irradiation (RAPID) 2007
Developing advanced practice roles in radiation therapy: Letting the evidence speak 2007
Difficulties associated with treatment optimization of high dose rate brachytherapy distributions for treatment of the endometrium with vaginal cylinders 2007
Dosimetric effects of immediate post-mastectomy breast reconstruction on chest wall radiotherapy 2007
Endoscopic-Guided Brachytherapy (EGB) for the palliation of advanced esophageal cancers 2007
Evidence to support improving cancer patient supportive care through community nursing: Results of a prospective study 2007
Feasibility testing of a quality assurance process for a cone-beam CT enabled online planning and treatment model for palliative radiotherapy 2007
High dose rate intraluminal Brachytherapy (HDRILBT) in lung cancer: A review of two years 2007
High frequency ultrasound Imaging of cell structural changes following radiation therapy 2007
Is body mass index a predictor for rectal dosimetry and toxicity in 125I permanent implant for low-risk prostate cancer? 2007
Long term urinary sequelae following iodine 125 prostate brachytherapy 2007
Ontario radiation oncology residents needs in the PGY-1 year - Residents' perspective survey 2007
Pain flare following radiotherapy for painful bone metastases: A joint effort of three cancer centres to determine the incidence 2007
Patterns of end of life cancer care: Health service use and predictors 2007
Plasma membrane and cytoplasmic activated EGF receptor predicts survival and cytoplasmic activated Erk predicts tumour response in locally advanced NSCLC patients treated with chemo-radiotherapy 2007
Preliminary evaluation of diffusion MRI to assess liver radiotherapy 2007
Relationships between PSA bounce and definitions of biochemical failure following I-125 brachytherapy for localized, low-risk prostate cancer 2007
Secondary malignancies among survivors of Hodgkin's lymphoma: An institutional review of the current screening practices for breast cancer following thoracic irradiation 2007
The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry 2007
The value of CT Imaging for treatment planning for brachytherapy in lung cancer 2007
Treatment of large fields for head and neck IMRT 2007
Using high-frequency spectroscopic ultrasound to monitor radiation and chemotherapy effects in lymphomas 2007
What is adequate radiotherapy quality assurance in phase III clinical trials involving radiation therapy? 2007
Worklife in Brachytherapy 2007
Assessment of intra-fraction motion for on-line planning and delivery of radiotherapy for patients with spinal metastases 2007
Human papilloma virus phv infection. Prevalence, clinical presentation and relevance of various protein markers in squamous cell carcinoma of head and neck (SCCHN) 2007
Organ preservation by induction chemotherapy and CT-based 3D radiotherapy in patients with advanced laryn geal and hypopharyngeal carcinomas 2007
Acute normal tissue reaction (moist desquamation) in patients with early breast cancer treated with 30Gy in 6 fractions over 15 days: Results of a pilot study. 2006
10 Acute phase response reactants as an objective measure of mucosal toxicity in head and neck cancer patients undergoing radical radiation therapy with or without concurrent chemo-therapy 2006
106 What is the impact of 4D CT on the planning of esophageal cancer? 2006
129 Inter-observer variability in gross tumour volume delineation in locally advanced non-small cell lung cancer cases: An institutional review 2006
162 Radiation dose to the internal pudendal arteries from iodine 125 prostate brachytherapy 2006
169 The impact of positron emission tomography (PET) in stage III non-small cell lung cancer: A prospective randomized clinical trial-improving clinical trials accrual using screening log evaluations 2006
183 Can an In Vitro Assay Predict Radiation Sensitivity in Patients with Carcinoma of the Prostate? 2006
202 Research and professional development: Video/phone Conference as a format for advancements in palliative radiotherapy 2006
226 Timing of androgen deprivation therapy after radical radiotherapy failure — A survey of Canadian practitioners 2006
28 Supportive care service needs of newly diagnosed cancer patients: Results of a population based study 2006
34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP) 2006
43 Self-shielding character of a tomotherapy unit in a replacement strategy: Economic considerations 2006
53 Initial results of a canadian feasibility study of accelerated partial breast irradiation (APBI) using 3-D conformal radiation therapy (3D CRT) 2006
63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome 2006
69 The impact of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) on radiotherapy planning in carcinoma of the esophagus 2006
121 The use of bisphosphonates in men with hormone-refractory prostate cancer: A systematic review of randomized trials 2005
138 Inflammatory serum markers as an objective measure of radiation mucositis in head and neck cancer 2005
14 Randomized Trial Comparing Iridium Plus External-Beam Radiation Therapy with External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate 2005
169 Measuring quality of work-life: A participatory approach in a Canadian Cancer Centre 2005
178 Advanced practice in radiation therapy: What's happening in Canada? 2005
201 Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT PLANS 2005
202 Relationship of the International Prostate Symptom Score with urinary flow studies, and catherization rates following iodine 125 prostate brachytherapy 2005
212 Resection of radiosurgically treated recurrent brain metastases: Pathological findings and subsequent survival 2005
448 The Use of IviewGT EPIDS for monthly QA of the MLC and jaw settings 2005
58 Radiation target volume delineation (TVD) using FDG-PET and contrast enhanced CT (CECT) for patients with head and neck cancer 2005
73 A prospective study to evaluate the need for an immobilization device for treating modified mantle fields in lymphoma patients 2005
95 Stereotactic program development in the management of meningioma 2005
Evaluation of inflammatory serum proteins as an objective measure of radiation induced mucositis in patients receiving radical radiation with or without concurrent chemotherapy 2004
A study examining epidermal growth factor receptor, p53, and Bcl-2 expression in patients with stage III and IV squamous cell carcinoma of the head and neck treated with concomitant chemo-radiotherapy. 2004
Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT plans. 2004
Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-Crt plans 2004
Clinical screening for lymphedema in breast cancer patients: Validation of Canadian guidelines. 2004
Computerized tomographic simulation compared to clinical mark-up in palliative radiotherapy: A prospective study 2004
Correlation between two surrogate outcomes: Post-radiotherapy biopsy (PRB) and PSA failure (BCF): Results from a randomized hypofractionated study in localized prostate cancer 2004
How can we use genomics to understand non-targeted effects of radiotherapy? 2004
Lymphedema in breast cancer patients screened during the first year of a randomized trial: Is treatment always the cause? 2004
Malignant thymoma: A review of treatment experience from two Canadian institutions. 2004
Mitogen-activated protein kinase (MAPK) expression and activation in non-small cell lung cancer (NSCLC): Investigating their prognostic significance and role in radiation responses. 2004
Penile brachytherapy: Results for 49 patients 2004
Pre-treatment assessment of repositioning accuracy of patients immobilized using the VBH HeadFIX system. 2004
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Does dose escalation improve local recurrence free survival and disease free survival? 2004
Randomized prospective study on the role of high dose rate intraluminal brachytherapy (HDRILBT) in palliation of symptoms in advanced non small cell lung cancer (NSCLC) treated with radiation alone 2004
Results of a randomised trial of follow-up strategies for breast cancer: Family physician versus cancer centre care 2004
The use and toxicity of steroids in the management of patients with brain metastases. 2004
Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns 2004
Which radiation regimen should be used for Bowen's disease of the skin? 2004
Brachytherapy for penile cancer: results for 49 patients 2004
The role of high dose rate endobronchial brachytherapy in the palliation of patients with non-small cell lung cancer: a practice-guideline 2004
Real-time remote education and knowledge exchange in medical physics using the internet 2003
Response to: Comment on Wu et al's article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer.. 206:110804. 2025
Radiation therapy and immigration status in women with breast cancer.. 205:110774. 2025
Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial.. 202:110605. 2025
102 Inequity and the Traveled Distance to Receive Radiotherapy in Brazil: A Cohort Study. 198:s46. 2024
124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial. 198:s54-s55. 2024
131 Modified Delphi Consensus on Interventions for Radiation Dermatitis in Breast Cancer: A Canadian Perspective. 198:s57. 2024
163 Stereotactic Body Radiotherapy for Para-Aortic Lymph Nodes for Gynaecological Cancers. 198:s69. 2024
181 The Projected Global Shortage of Brachytherapy by 2040: Required Investments to Address the Shortfall. 198:s76-s77. 2024
23 Stereotactic Body Versus Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for High-Risk Prostate Cancer (HR-PC); Early Results of PBS: A Phase II Randomized Trial (NCT03380806). 198:s13-s14. 2024
Letter to the Editor. 197:110350-110350. 2024
Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. 201:110439-110439. 2024
1359: Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16. 194:s2426-s2427. 2024
Applying the fragility index to randomized controlled trials evaluating total neoadjuvant therapy for rectal cancer: A methodological survey. 194:110148-110148. 2024
131 Proton arc therapy: advantages over conventional proton therapy and impact on range uncertainties. 192:S152-S156. 2024
LUMINA: Using molecular biomarkers to guide decision making for breast radiotherapy. 190:110074-110074. 2024
113 Final Results from a Prospective Randomized Pilot Trial of Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses (RADSTER). 186:S52-S52. 2023
114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. 186:S53-S53. 2023
128 Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer - A Secondary Analysis of the Lustre Randomized Trial. 186:S59-S59. 2023
146 Five-Year Renal Function Outcomes After Sabr for Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium of the Kidney (IROCK). 186:S66-S67. 2023
147 Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). 186:S67-S67. 2023
251 Prostate Specific Membrane Antigen Positron Emission Tomography for Patients with Recurrent Prostate Cancer (PREP) - A Prospective, Multicentre Registry. 186:S108-S108. 2023
300 Stereotactic Radiotherapy for the Re-Treatment of Pelvic and Para-Aortic Disease in Gynecologic Cancers. 186:S127-S128. 2023
307 the Effectiveness and Safety of Stereotactic Body Radiation Therapy in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review. 186:S130-S130. 2023
321 Comparison of Patient-Specific Quality Assurance Results from a Deliver-Log Based Calculation System and Dose Reconstruction in Patient Anatomy Based on Phantom Measurements. 186:S136-S136. 2023
40 Proton Therapy Mediates Dose Reductions to Critical Brain Organs at Risk Which are Associated with Better Cognition in Children with Medulloblastoma. 186:S21-S21. 2023
PO-1332 Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation. 182:S1066-S1066. 2023
Pan-Canadian consensus recommendations for proton beam therapy access in Canada. 176:228-233. 2022
139: Radiotherapy Dose, FDG-PET Utilization and Survival Outcomes of Unresected Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Ontario Population Outcomes of Contemporary Radiotherapy Alone and Standard of Care Chemo-Radiotherapy. 174:S59-S60. 2022
179: The Evolution of Technology in the Management of Early-Stage (T1) Cancer of the Larynx, an Institutional Review of Radiation Therapy Outcomes. 174:S74-S74. 2022
30: Statin Therapy in Patients Undergoing Short-Course Neoadjuvant Radiotherapy for Rectal Cancer. 174:S15-S16. 2022
33: A Prospective Randomized Parallel-Controlled Pilot Trial of Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses - Initial Results. 174:S17-S17. 2022
44: Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multi-Centre Analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK). 174:S21-S22. 2022
5: Long Term Toxicities of Adolescent and Young Adult Survivors of Cervix Cancer Who Underwent Radiation Therapy: A Cross-Sectional Analysis. 174:S5-S6. 2022
68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. 174:S31-S31. 2022
75: Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncologic and Renal Function Outcomes. 174:S34-S34. 2022
88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy. 174:S39-S39. 2022
OC-0104 Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes. 170:S88-S88. 2022
100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017. 163:S44-S44. 2021
132: Changes in the Incidence of Cervical Squamous Carcinoma/Carcinoma in Situ in Ontario Following the Approval of a Human Papillomavirus Vaccine. 163:S56-S57. 2021
151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer. 163:S64-S64. 2021
152: Organ at Risk Dose Constraints in Stereotactic Ablative Radiotherapy: A Systematic Review of Active Clinical Trials. 163:s64-s65. 2021
170: Real-World Outcomes of Chemoradiation and Consolidative Durvalumab in Unresectable Stage III Non-Small-Cell Lung Cancer – A Systematic Review. 163:S72-S72. 2021
18: PSMA-PET-Based Response Assessment of Metastatic Prostate Cancer Response to Radiotherapy: A Case Series. 163:S11-S11. 2021
23: Cost-Effectiveness of Sabr in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-Comet Randomized Trial. 163:S13-S13. 2021
37: Comparison of Recurrence with High Retropharyngeal Nodal-Sparing Radiation Technique in HPV-Related and HPV-Unrelated Oropharyngeal Cancer in the IMRT Era. 163:S18-S19. 2021
42: Understanding End-of-Life Cancer Care in Canada: an Updated 12-Year Retrospective Analysis of Three Provinces’ Administrative Health Care Data. 163:S20-S21. 2021
57: Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus (Spartacus): A Multi-Centre Prospective Trial Evaluating Acute Toxicities and Patient Reported Outcomes. 163:S27-S27. 2021
Management of gynecologic cancer: Choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. 151:15-16. 2020
184: Enabling Access to Cervcial Cancer Radiotherapy in Uganda: 10 Year Update on Road to Care. 150:S79-S79. 2020
194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?. 150:S83-S83. 2020
198: Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic and Oligoprogressive Gynecologic Cancers: Clinical Outcomes of a Single Institution Analysis. 150:S84-S84. 2020
202: Cost-Effectiveness of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) in the Treatment of Localized Renal Cell Carcinoma. 150:S86-S86. 2020
206: A Randomized Phase Ii Trial of Prostate Boost Irradiation with Stereotactic Body Radiotherapy (SBRT) in High-Risk Prostate Cancer. The Pbs Trial. 150:S87-S88. 2020
211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). 150:S89-S90. 2020
212: Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study. 150:S90-S90. 2020
36: Surgery Versus SBRT for Early-Stage Nsclc in Octogenarians and Nonagenarians: An Overall Survival Difference?. 150:S19-S19. 2020
4: Caro Acura 2016 Primary Analysis of a Phase II Study of Metastasis-Directed Ablative Therapy to Psma (18F-DCFPYL) Pet-Mr/ Ct Defined Oligorecurrent Prostate Cancer. 150:S6-S6. 2020
62: A Prospective Provincial Psma-Pet Registry for Recurrent Prostate Cancer: Preliminary Results. 150:S30-S30. 2020
69: Radiotherapy in Patients with Cardiovascular Implantable Electronic Devices: A Survey of Multi-Disciplinary Radiation Oncology Professionals. 150:S32-S33. 2020
77: Dosimetric Comparison of Conformal Radiation Therapy (Crt), Imrt and Vmat for Esophageal Cancer Treated with External Radiation. 150:S35-S36. 2020
8: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-Comet Randomized Trial. 150:S7-S7. 2020
92: Radiation Dose to Organs At Risk After High Dose Rate Brachytherapy for Esophageal Cancer Patients. 150:S41-S41. 2020
95: The Role of Brachytherapy in Saving Hospital Resources in Esophageal Cancer. 150:S42-S43. 2020
96: Intraoperative Mri-Guided Brachytherapy for Cervical Cancer: An Institutional Experience of Treatment Workflow, Planning and Patient Toxicity. 150:S43-S43. 2020
9: A Phase Ii Multicentre Trial of Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy. 150:S7-S8. 2020
International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. 142:180-185. 2020
105 Cyberknife Stereotactic Radiosurgery for Treatment of Benign Intracranial Meningioma: Long-Term Safety and Efficacy. 139:S46-S47. 2019
122 A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. 139:S53-S53. 2019
126 Engaging Inter-Professional Collaboration to Improve Resident Treatment Planning Knowledge and Skills. 139:S55-S55. 2019
146 A Comparison of Stereotactic Body Radiotherapy Modalities: Volumetric Modulated Arc Therapy Versus Intensity Modulated Radiation Therapy in Treatment of Kidney Cancer. 139:S63-S63. 2019
158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. 139:S68-S68. 2019
167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy. 139:S71-S72. 2019
189 Bone Scans in the Management of Metastatic Castrate-Resistant Prostate Cancer: Survey of Patterns of Practice in Canadian Radiation Oncologists, Medical Oncologists and Urologists. 139:S79-S80. 2019
19 Stereotactic Body Radiotherapy for Large Primary Large Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). 139:S11-S11. 2019
2 Drive: Defining Radiorecurrent Intraprostatic Target Volumes. 139:S4-S4. 2019
202 Characterizing the Initiation, Completion, and Integration of Entrustable Professional Activity Assessments in Radiation Oncology Residency Training and Clinical Workflow: An Institutional Pilot of Competence by Design. 139:S85-S85. 2019
216 The Impact of Routine ESAS Use on Emergency Department Visits and Hospitalizations: A Population-Based Retrospective Matched Cohort Study. 139:S90-S91. 2019
40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy. 139:S20-S20. 2019
91 Quality of Life Outcomes After Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. 139:S41-S41. 2019
92 Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. 139:S41-S42. 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. 135:19-24. 2019
Single versus multifraction radiotherapy for spinal cord compression: A systematic review and meta-analysis. 134:55-66. 2019
MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML). 129:540-547. 2018
Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial. 126:541-546. 2018
Radiation therapy quality indicators for invasive breast cancer. 123:288-293. 2017
Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. 121:414-419. 2016
140: Indentification of Curculating MIRNA Associated with Development of Castrate Resistance in High-Risk and Biochemically Recurrent Prostate Cancer Patients. 120:S52-S52. 2016
146: Current Practice of External Beam Radiotherapy and Brachytherapy for Management of Endometrial Cancer in Ontario, Canada. 120:S54-S54. 2016
148: Evaluation of the Rationale for Lingual Tonsillectomy in the Diagnostic Work-Up of Head and Neck Squamous Cell Carcinoma of Unknown Primary: Impact of Identifying Small Tongue Base Primary Tumours on IMRT Characteristics and Clinical Outcomes. 120:s55. 2016
14: Current Practice of Brachytherapy and External Beam Radiotherapy for Cervical Cancer in Ontario, Canada. 120:S5-S6. 2016
159: Phase I Study of NEO-Adjuvant Stereotactic Body Radiotherapy (SBRT) in Operable Patients with Borderline Resectable Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (Linnearre I Study: NCT02433574). 120:S58-S59. 2016
169: Systematic Review of Patient Reported Quality of Life Following Stereotactic Ablative Body Radiotherapy for Primary and Metastatic Liver Cancer. 120:S62-S62. 2016
202: Brachytherapy for Endobronchial Metastasis: An Effective Method of Achieving Palliative Relief of Cough, Hemoptysis, Chest Pain and Dyspnea. 120:S74-S74. 2016
228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. 120:S83-S83. 2016
233: Sinonasal Undifferentiated Carcinoma with Brain Metastasis: A Case Report and Review of Literature. 120:S85-S85. 2016
240: The Management of Small Cell Lung Cancer with Radiotherapy - A Pan-Canadian Survey of Radiation Oncologists. 120:S87-S87. 2016
249: A Prospective Study Validating the EORTC QLQ–BM22 Bone Metastases Module in Patients With Painful Bone Metastases. 120:S90-S91. 2016
24: Reduction in Radiotherapy Dose to the Submandibular Gland in Patients with Oral Cavity Cancer using a Novel Surgical Technique and IMRT. 120:S9-S10. 2016
250: Minimal Clinically Important Differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-Pal Modules in Patients with Bone Metastases. 120:S91-S91. 2016
33: Brachytherapy as a Sole Treatment Modality for Early Esophageal Cancer (EEC). 120:S12-S13. 2016
73: Preliminary Results from a Pilot Study on the Role of Dual Source Computed Tomography for Cardiac Sparing in Left Breast Radiotherapy. 120:S28-S29. 2016
90: Combined Salicylate (SAL) - Metformin (MET) Treatment Induces Increased Tumour Suppression and Radiosensitization in Preclinical Models of Prostate Cancer (PRCA). 120:S35-S35. 2016
Metformin for chemo-radio-sensitization of NSCLC. 120:363-364. 2016
A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. 119:208-212. 2016
Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. 118:547-551. 2016
A dosimetric study of cardiac dose sparing using the reverse semi-decubitus technique for left breast and internal mammary chain irradiation. 118:187-193. 2016
Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U). 115:141-148. 2015
216: A novel dual-modality optical tomography and x-ray system for small animal radiation research platform. 110:S105-S105. 2014
PO-0661: CogState computerized memory tests in patients with br ain metastases: Secondary endpoint results of RTOG 0933. 111:S5-S5. 2014
The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. 109:204-210. 2013
65 INTEGRATED ON-BOARD X-RAY AND BIOLUMINESCENCE TOMOGRAPHY TO GUIDE FOCAL IRRADIATION OF SOFT TISSUE TARGETS IN SMALL ANIMALS. 102:S23-S23. 2012
Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells. 102:459-465. 2012
Total quality culture in radiotherapy departments across Ontario. 99:90-93. 2011
Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: A prospective multi-centre randomized trial of the International Atomic Energy Agency. 97:488-494. 2010
167 A PRELIMINARY INVESTIGATION OF TOTAL QUALITY CULTURE IN RADIOTHERAPY DEPARTMENTS ACROSS ONTARIO, CANADA: A PROVINCIAL SURVEY. 92:S53-S53. 2009
38 OUTCOMES OF YOUNG WOMEN WITH DCIS TREATED WITH BREAST-CONSERVING SURGERY AND RADIOTHERAPY: A POPULATION-BASED ANALYSIS. 92:S12-S13. 2009
73 HIPPOCAMPAL RADIATION EXPOSURE MAY TEMPORARILY IMPAIR MEMORY IN A DOSE-DEPENDENT MANNER IN PATIENTS RECEIVING RADIOSURGERY FOR BENIGN NEUROLOGIC DISORDERS. 92:S23-S24. 2009
Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis. 88:1-9. 2008
MOSFET detectors in quality assurance of tomotherapy treatments. 86:242-250. 2008
The role of radiation therapy in malignant pleural mesothelioma: A systematic review. 80:13-18. 2006
59 Radiation — Induced apoptosis of lymphocytes to predict normal tissue late toxicity from radiotherapy. 76:S18-S18. 2005
93 Radiation-induced apoptosis of lymphocytes to predict late toxicity from radiotherapy. 72:S29-S29. 2004
Accuracy of ultrasound in localization of breast boost field. 72:61-66. 2004
Recommendations for implementation of high dose rate 192Ir brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agency. 64:297-308. 2002
The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. 64:239-250. 2002
53 Brachytherapy alone in palliation of advanced esophageal carcinoma - combined research protocol (CRP), international atomic energy agency study group, vienna - a report of a randomized prospective multicentric study. 55:33-34. 2000
Erratum. 50:371-371. 1999
Oxygenation predicts radiation response and survival in patients with cervix cancer. 48:149-156. 1998
Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. 47:277-284. 1998
Accelerated radiation therapy for primary lymphoma of the brain. 47:191-195. 1998
Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix. 33:187-194. 1994
Variation in mantle technique: implications for establishing priorities for quality assurance in clinical trials. 23:144-149. 1992

Radiotherapy and Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)